In Q2 2025, India’s healthcare and pharma sector saw 57 transactions totalling $1.3 billion—a 50% slide from Q1 and 20% fewer deals—per Grant Thornton Bharat. The dip spans IPOs, QIPs, and other M&A, signalling investor caution and slower deal-making momentum.
Q2 healthcare & pharma deals drop to $1.3 billion
